Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their ordinary share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On July 13, 2011, various directors and executives increased their holdings in GlaxoSmithKline plc ordinary shares. These purchases were executed at a price of 1,367.69 pence per share and resulted from the re-investment of dividends paid to shareholders on July 7, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: July 13, 2011.
- Share Price: 1,367.69 pence per share.
- Transaction Type: Dividend re-investment leading to an increase in shareholdings.
- Participants: Includes Mr. A P Witty, Dr. M M Slaoui, Mr. S M Bicknell, Mr. J M Clarke, Mr. M Dunoyer, Mr. E J Gray, Mr. S A Hussain, Mr. D S Redfern, Mr. J R Stéphenne, Ms. C Thomas, Mr. P C Thomson, and Dr. P J T Vallance.
- Notification Date: The company was advised of these transactions on July 14, 2011.